EXPLORE!

Delhi High Court dismisses pleas against Centre's ban on anti-diabetic FDC medicines

  1134 Views

eMediNexus    10 January 2019

New Delhi: The Delhi High Court has rejected a batch of pleas challenging the Centres notification banning manufacture and sale of fixed dose combination (FDC) drugs used for treatment of Type-II diabetes. Justice Vibhu Bakhru said there was no ground to interfere with the central governments September 7, 2018, notification and dismissed the petitions filed by eight pharma companies. The Centre had banned the FDCs of formulation of metformin, pioglitazone and glimepiride of varying compositions. These FDCs are used for treatment of type 2 diabetes mellitus and to improve the glycemic control as an adjunct to diet and exercise… (ET Health, Jan 9, 2019)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.